AbbVie (ABBV) Operating Margin (2012 - 2026)
AbbVie (ABBV) reported Operating Margin of 26.6% for Q1 2026, down 138.0% year-over-year from 69.99% in Q1 2025, and down 2.73% quarter-over-quarter from 27.34% in Q4 2025.
AbbVie (ABBV) Operating Margin (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Operating Margin data on file, last reported at 26.6% in Q1 2026.
- Operating Margin for Q1 2026 came in at 26.6%, down 138.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.41% (up 685.0% YoY), and the FY2025 annual result was 24.65%, up 843.0% from the prior year.
- Operating Margin eased to 26.6% in Q1 2026 per ABBV's latest filing, from 27.34% in the prior quarter.
- Over five years, Operating Margin peaked at 36.39% in Q4 2022 and troughed at 9.87% in Q4 2024.
- A 5-year average of 24.21% and a median of 26.6% in 2026 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin sank 3221 bps in 2024, then jumped 3721 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 36.39% in 2022, then slumped by 39 bps to 22.34% in 2023, then sank by 144 bps to 9.87% in 2024, then surged by 377 bps to 27.34% in 2025, then decreased by 3 bps to 26.6% in 2026.
- Business Quant data shows ABBV's Operating Margin at 26.6% in Q1 2026, 27.34% in Q4 2025, and 12.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | -1.58% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.60% |
| Dec 31, 2025 | 27.34% |
| Sep 30, 2025 | 12.07% |
| Jun 30, 2025 | 31.73% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | -9.87% |
| Sep 30, 2024 | 26.49% |
| Jun 30, 2024 | 27.64% |
| Mar 31, 2024 | 22.73% |
| Dec 31, 2023 | 22.34% |
| Sep 30, 2023 | 16.38% |
| Jun 30, 2023 | 32.55% |
| Mar 31, 2023 | 22.64% |
| Dec 31, 2022 | 36.39% |
| Sep 30, 2022 | 31.08% |
| Jun 30, 2022 | 22.59% |
| Mar 31, 2022 | 34.84% |
| Dec 31, 2021 | 34.09% |
| Sep 30, 2021 | 30.02% |
| Jun 30, 2021 | 31.81% |